Aegis Sciences Corporation

Aegis Sciences Corporation was paid $193.81M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 28% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Tennessee

Rank by total paid#1 of 70

Median peer was paid$141K

This provider vs. median1,374×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,445,258	$26.26M
2019	1,152,434	$25.01M
2020	677,343	$16.69M
2021	962,903	$25.46M
2022	991,254	$28.85M
2023	1,203,674	$34.70M
2024incomplete	978,827	$36.85M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	28%	1,088,897	689,601	$54.95M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	18%	509,138	361,097	$34.86M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	18%	1,272,440	807,337	$33.93M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	14%	422,715	248,673	$27.22M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.4%	380,518	263,818	$12.47M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	4.2%	117,406	95,856	$8.22M
82542		1.0%	341,199	235,692	$1.99M
84228		<1%	330,928	235,447	$1.61M
80325		<1%	134,507	99,409	$978K
80348		<1%	140,600	104,321	$864K
80373		<1%	133,038	99,359	$820K
80361		<1%	143,555	106,485	$777K

92 more codes

80356		<1%	141,871	$760K
80323		<1%	81,243	$752K
80354		<1%	139,639	$676K
80365		<1%	143,615	$672K
80366		<1%	114,610	$667K
80321		<1%	88,670	$644K
80355		<1%	120,921	$641K
80358		<1%	141,329	$641K
80369		<1%	109,420	$636K
80359		<1%	140,140	$611K
80337		<1%	46,215	$611K
80346		<1%	108,351	$609K
80353		<1%	139,928	$594K
80344		<1%	47,938	$548K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	34,015	$540K
80334		<1%	42,866	$521K
80338		<1%	54,130	$470K
80377		<1%	41,381	$449K
80364		<1%	50,514	$366K
80362		<1%	62,695	$330K
82415		<1%	49,372	$327K
80372		<1%	52,031	$317K
80357		<1%	39,480	$270K
80368		<1%	36,653	$256K
80340		<1%	18,562	$247K
80347		<1%	34,242	$227K
80370		<1%	28,288	$226K
80360		<1%	45,929	$210K
80345		<1%	32,059	$160K
80363		<1%	16,077	$139K
80371		<1%	25,265	$110K
80349		<1%	27,299	$109K
80352		<1%	24,250	$98K
80341		<1%	14,760	$96K
80375		<1%	6,642	$62K
80339		<1%	8,834	$58K
80374		<1%	9,232	$54K
83992		<1%	10,161	$45K
80335		<1%	3,335	$38K
80320		<1%	5,005	$31K
80324		<1%	4,704	$29K
80074		<1%	1,822	$26K
80332		<1%	3,736	$26K
80376		<1%	5,093	$25K
80061	Lipid panel	<1%	3,432	$17K
80342		<1%	4,584	$16K
84443	Thyroid stimulating hormone (TSH)	<1%	4,207	$15K
80053	Comprehensive metabolic panel	<1%	5,465	$14K
82652		<1%	2,286	$14K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	2,087	$13K
83036	Hemoglobin; glycosylated (A1C)	<1%	3,313	$13K
80050	General health panel	<1%	451	$12K
84481		<1%	2,057	$12K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	6,163	$11K
80367		<1%	851	$9K
84439		<1%	2,140	$9K
84146		<1%	521	$5K
86780		<1%	758	$5K
86696		<1%	671	$4K
82607		<1%	585	$4K
86695		<1%	816	$3K
G6056	Opiate(s), drug and metabolites, each procedure	<1%	155	$3K
80164		<1%	499	$2K
82746		<1%	294	$2K
86803		<1%	516	$2K
87340		<1%	397	$1K
82248		<1%	582	$1K
85027		<1%	358	$935.12
80171		<1%	75	$881.47
G6031	Benzodiazepines	<1%	95	$837.12
G6053	Methadone	<1%	62	$547.46
80178		<1%	185	$478.45
86769		<1%	17	$441.90
84403		<1%	35	$351.35
87521	Neg quan hep c or qual rna	<1%	15	$325.05
G6044	Cocaine or metabolite	<1%	47	$295.02
G6042	Amphetamine or methamphetamine	<1%	46	$285.77
86705		<1%	67	$241.17
84702		<1%	48	$217.75
82465		<1%	70	$199.20
84100		<1%	69	$117.42
86709		<1%	26	$100.54
82947		<1%	41	$98.31
80076		<1%	13	$56.96
84520		<1%	17	$37.23
84450		<1%	12	$30.25
81226		0%	59	$0.00
G6052	Meprobamate	0%	50	$0.00
82544		0%	68	$0.00
81225		0%	58	$0.00
81227		0%	54	$0.00
G0431	Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPRIESTLEY, DAVID (CHIEF FINANCIAL OFFICER)

Same official

Other billing entities under PRIESTLEY, DAVID

Full network →

Provider	Location	Paid
Priestley Mental Health INC	Preston, ID	$874K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.